| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by LCR.
Page 6: 1 2 3 4 5 6 7
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 1501 | 0 | 0 | 674 1998 BIOTECHNOLOGY LAW REPORT 17(3):361-362 [Anon] FDA grants orphan drug designation to thalidomide as treatment for primary brain cancers | 0 | 0 |
| 1502 | 0 | 0 | 675 1998 BIOTECHNOLOGY LAW REPORT 17(5):596-597 [Anon] Notorious teratogen wins FDA approval for leprosy - Thalidomide will be most tightly regulated drug ever | 0 | 0 |
| 1503 | 0 | 0 | 676 1998 BLOOD 92(10):235B-235B Costa PT; Leaf RMLV; Morais LO; Ribeiro RA Thalidomide (TLD) and pentoxifylline (PTX) prevent the development of chronic cardiomyopathy provoked by doxorubicin (DXR) in rats without inhibiting its antitumoral effect. | 0 | 2 |
| 1504 | 0 | 0 | 677 1998 BLOOD 92(10):279B-279B Lim SH; Maclean R Thalidomide in IgA multiple myeloma. | 0 | 0 |
| 1505 | 0 | 0 | 678 1998 BLOOD 92(10):318A-318A Singhal S; Mehta J; Eddlemon P; Gray P; Cromer J; Desikan R; Ayers D; Siegel D; Munshi N; Anaissie E; Kantarjian H; Zeldis J; Barlogie B Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM). | 0 | 20 |
| 1506 | 0 | 0 | 679 1998 BLOOD 92(10):344B-344B Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Meller S; Atra A; Pinkerton CR; Singhal S Thalidomide in GVHD - S anti-GVHD effect separable from the antiangiogenesis? | 0 | 4 |
| 1507 | 0 | 0 | 680 1998 BONE MARROW TRANSPLANTATION 21:S113-S113 Anagnostopoulos A; Fassas A; Giannaki E; Sakellari I; Tzarou V; Smias C; Lalayanni C; Papaioannou G; Gakos E Treatment of resistant chronic GVHD with thalidomide. | 0 | 0 |
| 1508 | 0 | 0 | 687 1998 CHEMISTRY & INDUSTRY (15):591-591 [Anon] Concern over US thalidomide approval | 1 | 0 |
| 1509 | 0 | 0 | 689 1998 CIRCULATION 98(17):247-247 Dibbs ZI; Longo T; Muller GW; Zeldis J; Sivasubramanian N; Mann DL Thalidomide and thalidomide analogs suppress TNF alpha secretion by myocytes | 0 | 0 |
| 1510 | 0 | 0 | 696 1998 EUROPEAN CYTOKINE NETWORK 9(3):367-367 Corral LG; Haslett PAJ; Ocampo C; Muller GW; Wong ML; Stirling D; Kaplan G Two distinct classes of thalidomide analogues which shape potent TNF-alpha inhibitory activity, modulate other cytokines differently | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1511 | 0 | 0 | 698 1998 FASEB JOURNAL 12(4):A262-A262 Rowland TL; McHugh SM; Ewan PW; Lachmann PJ; Dearman RJ; Kimber I Down-regulation of T-cell and non-T-cell derived tumor necrosis factor alpha by thalidomide and dexamethasone | 0 | 0 |
| 1512 | 0 | 0 | 699 1998 GASTROENTEROLOGY 114(4):A1008-A1008 Kenet G; Avni Y; Aeed H; Shirin H; Matas Z; Zaidel L; Galor S; Hershkovitz R; Bruck R Iodoacetamide-induced colitis in rats is inhibited by thalidomide. | 0 | 0 |
| 1513 | 0 | 0 | 700 1998 GEBURTSHILFE UND FRAUENHEILKUNDE 58(3):M55-M58 Kosenow W Forty years ago: Thalidomide and its consequences | 0 | 0 |
| 1514 | 0 | 0 | 702 1998 HEPATOLOGY 28(4):460A-460A Martinez L; Lopez-Talavera JC; Martinez M; Cadelina G; Pachon JC; Esteban R; Guardia J; Groszmann RJ Amelioration of the hyperdynamic syndrome of cirrhotic rats by thalidomide. | 0 | 0 |
| 1515 | 0 | 0 | 707 1998 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 280(10):872-872 Nightingale SL Thalidomide approved for erythema nodosum leprosum | 9 | 11 |
| 1516 | 0 | 0 | 711 1998 JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):516-516 Wolkenstein P; Latarget J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Milpied B; Bocquet H; Revuz J Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: Overmortality in treated group. | 0 | 0 |
| 1517 | 0 | 0 | 712 1998 JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):693-693 Brenneman S; Burns R; Vink A; Gaines E; Haake A; Gaspari A Thalidomide inhibits UVB-induced mouse epidermal cell apoptosis by a TNF-alpha dependent pathway. | 0 | 0 |
| 1518 | 0 | 0 | 720 1998 JOURNAL OF VASCULAR RESEARCH 35:54-54 Baatz H; Tonnessen B; Pleyer U; Hartmann C Antiinflammatory action of thalidomide: Modulation of leukocyte-endothelium interaction | 0 | 0 |
| 1519 | 0 | 30 | 721 1998 LANCET 351(9110):1197-1199 Dally A Thalidomide: was the tragedy preventable? | 6 | 16 |
| 1520 | 0 | 0 | 724 1998 LANCET 352(9124):298-298 Ault A Thalidomide makes a return to US health care | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1521 | 0 | 0 | 728 1998 MEDICAL LETTER ON DRUGS AND THERAPEUTICS 40(1038):103-104 [Anon] Thalidomide | 1 | 0 |
| 1522 | 0 | 0 | 730 1998 MOLECULAR BIOLOGY OF THE CELL 9:200A-200A Wilson K; Lancaster T; Boyd M; Taylor LD Inhibition of cell-cell contacts in T lymphoblastic cells during exposure to thalidomide. | 0 | 0 |
| 1523 | 0 | 0 | 732 1998 NATURE BIOTECHNOLOGY 16(8):695-695 [Anon] The problem with thalidomide's new incarnation | 0 | 0 |
| 1524 | 0 | 0 | 733 1998 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 357(4):R119-R119 Thiel R; Klug S Adhesion receptors on rat limb bud cells after treatment with a thalidomide derivative | 0 | 0 |
| 1525 | 0 | 0 | 734 1998 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 358(1):R479-R479 Bignone IM; Papale RM; Seoane M; Bazerque PM Thalidomide - New trends for therapeutical use | 0 | 0 |
| 1526 | 0 | 0 | 735 1998 NEUROLOGY 50(4):A208-A208 Poncelet AN; Maurer TA; Wu ZQ; Ng J; Badger J; Berger TG Peripheral neuropathy in HIV-infected patients with prurigo nodularis treated with thalidomide: Clinical and electrophysiologic features | 0 | 0 |
| 1527 | 0 | 0 | 736 1998 NEUROLOGY 50(4):A383-A384 Frennier JM; Abrey LE; Haimovitz-Friedman A; McLoughlin M; Rosenfeld MR Does thalidomide have a role in glioma angiogenesis? | 0 | 0 |
| 1528 | 0 | 0 | 743 1999 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 217:U88-U88 Konnecke WE; Smith AM; Khetani VD A two step synthesis of thalidomide. | 0 | 0 |
| 1529 | 0 | 0 | 744 1999 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 218:U58-U58 Luzzio FA; Thomas EM; Figg WD Stereoselective synthesis of thalidomide analogs. | 0 | 0 |
| 1530 | 0 | 0 | 749 1999 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 159(3):A271-A271 Lindsay L; Oliver S; Freeman S; Regis J; Krauss A; Kaplan G The role of thalidomide and steroid in modulating the expression of TNF-alpha (TNA-a) and IL-6 in the hyperoxic newborn rat lung. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1531 | 0 | 0 | 755 1999 ARTHRITIS AND RHEUMATISM 42(9):S91-S91 Connolly JE; Rigby WFC Thalidomide inhibits LPS induced activation of p38 and JNK stress activated kinase pathways. | 0 | 0 |
| 1532 | 0 | 0 | 756 1999 ARTHRITIS AND RHEUMATISM 42(9):S187-S187 Oliver SJ; Moreira A; Kaplan G Reduced fibrosis and normalization of skin structure in scleroderma patients treated with thalidomide. | 1 | 5 |
| 1533 | 0 | 0 | 757 1999 ARTHRITIS AND RHEUMATISM 42(9):S276-S276 Oliver SJ; Moreira A; Ozawa M; Krueger JG; Kaplan G Beneficial effects of thalidomide in sarcoidosis are associated with an enhanced Th1-type immune response | 0 | 0 |
| 1534 | 0 | 0 | 758 1999 ARTHRITIS AND RHEUMATISM 42(9):S373-S373 El Hassani S; Dougados M; Gombert B; Amor B; Breban M Treatment of severe retractory spondylarthopathy (SPA) with thalidomide: Results of an open study. | 2 | 6 |
| 1535 | 0 | 0 | 759 1999 ARTHRITIS AND RHEUMATISM 42(10):2259-2260 Gompel A; Frances C; Piette JC; Blanc AS; Cordoliani F; Piette AM Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al | 8 | 9 |
| 1536 | 0 | 0 | 760 1999 ARTHRITIS AND RHEUMATISM 42(10):2260-2260 Ordi J; Cortes F; Balada E; Mauri M; Vilardell M Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al - Reply | 0 | 0 |
| 1537 | 0 | 0 | 763 1999 BLOOD 94(10):124A-124A Neben K; Hawighorst H; Moehler TM; Egerer G; Punzel M; Van Kaick G; Ho AD; Goldschmidt H Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters. | 0 | 9 |
| 1538 | 0 | 0 | 764 1999 BLOOD 94(10):124A-124A Juliusson G; Celsing F; Turesson I; Adriansson M; Malm C Thalidomide frequently induces good partial remission and best response ever in patients with advanced myeloma and prior high dose melphalan and autotransplant. | 0 | 2 |
| 1539 | 0 | 0 | 765 1999 BLOOD 94(10):124A-125A Moehler TM; Neben K; Egerer G; Punzel M; Schmier J; Cremer F; Goldschmidt H; Ho AD Thalidomide plus CED-chemotherapy in patients with poor prognosis multiple myeloma. | 0 | 0 |
| 1540 | 0 | 0 | 766 1999 BLOOD 94(10):125A-125A Sabir T; Raza S; Anderson L; Jagannath S Thalidomide is effective in the treatment of recurrent. Refractory multiple myeloma (MM). | 0 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1541 | 0 | 0 | 767 1999 BLOOD 94(10):125A-125A Shima Y; Treon SP; Yoshizaki K; Tai YT; Hideshima T; Raje N; Chauhan D; Davies F; Schlossman R; Anderson KC Clinical and biological activity of thalidomide (Thal) in multiple myeloma (MM). | 0 | 11 |
| 1542 | 0 | 0 | 768 1999 BLOOD 94(10):158A-158A Koc S; Leisenring W; Flowers ME; Sullivan KM; Martin PJ Evaluation of thalidomide for the treatment of chronic graft-versus-host disease in "high risk" patients. | 0 | 1 |
| 1543 | 0 | 0 | 769 1999 BLOOD 94(10):308B-308B Chen CI; Adesanya A; Sutton DM; Brandwein J; Stewart AK Low-dose thalidomide in patients with advanced, refractory multiple myeloma. | 0 | 1 |
| 1544 | 0 | 0 | 770 1999 BLOOD 94(10):308B-308B Coleman M; Gelfand RM; Leonard JP Combination non-myelosuppressive therapy (thalidomide, clarithromycin, dexamethasone) for plasma cell myeloma: A preliminary report. | 0 | 2 |
| 1545 | 0 | 0 | 771 1999 BLOOD 94(10):311B-311B Kanard AM; Kane G; Thome SD; Goudreau J; Markovic SN Thalidomide associated with seizures and neuroradiologic features suggestive of reversible posterior leukoencephalopathy syndrome (RPLS) in the setting of multiple myeloma and renal failure. | 0 | 1 |
| 1546 | 0 | 0 | 772 1999 BLOOD 94(10):314B-315B Srkalovic G; Karam MA; McLain DA; Hussein MA Melphalan, thalidomide and decadron (MTD) for refractory/relapsed multiple myeloma (MM). | 0 | 1 |
| 1547 | 0 | 0 | 773 1999 BLOOD 94(10):315A-315A Cheng D; Kini AR; Rodriguez J; Burt RK; Peterson LC; Traynor AE Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients. | 0 | 8 |
| 1548 | 0 | 0 | 774 1999 BLOOD 94(10):316B-316B Wu K; Schaafsma MR; Smit WM; Neef C; Richel DJ Thalidomide as anti-angiogenesis treatment in patients with chemotherapy resistant multiple myeloma (MM). | 0 | 1 |
| 1549 | 0 | 0 | 775 1999 BLOOD 94(10):316A-316A Durie BGM; Stepan DE Efficacy of low dose thalidomide (T) in multiple myeloma. | 0 | 18 |
| 1550 | 0 | 0 | 776 1999 BLOOD 94(10):316A-316A Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed and refractory myeloma. | 0 | 9 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1551 | 0 | 0 | 777 1999 BLOOD 94(10):317A-317A Yaccoby S; Johnson CL; Mahaffey SC; Barlogie B; Epstein J Thalidomide metabolism and its anti-myeloma efficacy in vivo. | 0 | 1 |
| 1552 | 0 | 0 | 778 1999 BLOOD 94(10):317A-317A Schiller G; Vescio R; Berenson J Thalidomide for the treatment of multiple myeloma relapsing after autologous peripheral blood progenitor cell transplant. | 0 | 8 |
| 1553 | 0 | 0 | 779 1999 BLOOD 94(10):507A-507A Thomas DA; Aguayo A; Estey E; Albitar M; O'Brien S; Giles FJ; Beran M; Cortes J; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide as anti-angiogenesis therapy (RX) in refractory or relapsed leukemias. | 0 | 5 |
| 1554 | 0 | 0 | 780 1999 BLOOD 94(10):578A-578A Munshi N; Desikan R; Anaissie E; Zangari M; Badros A; Lim S; Toor A; Morris C; Eddlemon P; Ayers D; Roberson P; Barlogie B Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF as part of Total Therapy II in newly diagnosed multiple myeloma (MM): Influence of thalidomide (THAL) administration. | 0 | 7 |
| 1555 | 0 | 0 | 781 1999 BLOOD 94(10):603A-603A Desikan R; Munshi N; Zeldis J; Eddlemon P; Badros A; Zangari M; Singhal S; Mehta J; Ayers D; Lim S; Wilson C; Anaissie E; Crowley J; Barlogie B Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease. | 0 | 3 |
| 1556 | 0 | 0 | 782 1999 BLOOD 94(10):604A-604A Weber DM; Gavino M; Delasalle K; Rankin K; Giralt S; Alexanian R Thalidomide alone or with dexamethasone for multiple myeloma. | 0 | 27 |
| 1557 | 0 | 0 | 783 1999 BLOOD 94(10):661A-661A Raza A; Lisak L; Andrews C; Little L; Muzammil M; Alvi S; Mazzoran L; Zorat F; Akber A; Ekbal M; Razvi S; Venugopal P Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes (MDS). | 0 | 9 |
| 1558 | 0 | 0 | 784 1999 BLOOD 94(10):702A-702A Thomas DA; Aguayo A; Giles FJ; Albitar M; O'Brien S; Cortes J; Faderl S; Bivins C; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide anti-angiogenesis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF). | 0 | 15 |
| 1559 | 0 | 1 | 795 1999 CLINICAL REHABILITATION 13(3):250-252 Newman RJ Shoulder joint replacement for osteoarthrosis in association with thalidomide-induced phocomelia | 0 | 0 |
| 1560 | 0 | 0 | 803 1999 GASTROENTEROLOGY 116(4):A745-A745 Kane SV; Ehrenpreis ED; Cohen LB; Hanauer SB; Cohen RD Therapeutic efficacy of thalidomide for patients with refractory Crohn's disease (CD) | 2 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1561 | 0 | 0 | 804 1999 GASTROENTEROLOGY 116(4):A767-A767 Macumber C; Wettstein AP; Vickers CR; Hing M; Edwards PD; Byrnes DJ; Meagher AP Thalidomide-effective therapy in chronic resistant inflammatory bowel disease. Department of gastroenterology. St. Vincent's Hospital, Sydney, Australia. | 2 | 3 |
| 1562 | 0 | 0 | 805 1999 GASTROENTEROLOGY 116(4):A837-A837 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Papadakis KA; Zeldis JB; Targan SR An open-label, stepwise dose-escalating pilot study to evaluate the safety, tolerance, & efficacy of low-dose thalidomide in the treatment of chronically-active, steroid-department Crohn's disease (CD) | 3 | 0 |
| 1563 | 0 | 0 | 806 1999 GASTROENTEROLOGY 116(4):A843-A843 Wedel S; Bauditz J; Suk A; Lochs H Efficacy of thalidomide in Crohn's disease. | 2 | 3 |
| 1564 | 0 | 0 | 819 1999 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S84-S84 Velez G; Robinson MR; Durbin T; Yuan P; Sung C; Whitcup SM Thalidomide-sustained release devices for choroidal neovascularization; An in-vitro analysis | 0 | 1 |
| 1565 | 0 | 0 | 820 1999 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S224-S224 Spraul CW; Kaven C; Amann J; Lang GK; Lang GE Effect of thalidomide, octreotide, and decortine on the migration and proliferation of RPE cells in vitro | 0 | 0 |
| 1566 | 0 | 0 | 822 1999 JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 103(1):S20-S20 Martinez A; Hernandez T; Hernandez V; Espinosa F Thalidomide for pertinacious vasculitic syndrome secondary to coxsackie A virus infection. | 0 | 0 |
| 1567 | 0 | 0 | 840 1999 LANCET 354(9182):925-925 Larkin M Low-dose thalidomide seems to be effective in multiple myeloma | 9 | 14 |
| 1568 | 0 | 0 | 841 1999 LANCET 354(9191):1705-1705 Larkin M Thalidomide continues to look promising as an anticancer agent | 1 | 1 |
| 1569 | 0 | 0 | 844 1999 MOLECULAR BIOLOGY OF THE CELL 10:75A-75A Taylor LD; Settles B; Wilson K; Mack C Investigation of the inhibition of cell adhesion by the Anti-TNF-alpha agent thalidomide utilizing in vitro fluorescence-based assays. | 0 | 0 |
| 1570 | 0 | 0 | 851 1999 NEUROLOGY 52(6):A424-A425 Li HW; Zhu LX; Karpati G; Nalbantoglu J Effect of thalidomide on growth of experimental intracerebral gliomas | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1571 | 0 | 0 | 854 1999 ONCOLOGY-NEW YORK 13(5):744-744 [Anon] Thalidomide shows promising results in patients with multiple myeloma | 0 | 0 |
| 1572 | 0 | 0 | 857 1999 PEDIATRIC RESEARCH 45(4):67A-67A Jakkula M; Le Cras TD; Abman SH Effects of fumagillin and thalidomide treatment on alveolarization in the developing rat lung | 0 | 4 |
| 1573 | 0 | 0 | 869 2000 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 219:U227-U227 Luzzio FA; Mayorov AV; Figg WD Thalidomide metabolites: Preparation of (+)-2-(N-phthalimido)- 4-hydroxyglutamic acid derivatives. | 0 | 0 |
| 1574 | 0 | 0 | 870 2000 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 220:U96-U96 Luzzio FA; Thomas EM; Figg WD Thalidomide analogs and metabolites: Cyclic and acyclic derivatives of 2S, 3S-2-N-phthalimido(3-hydroxy)ornithine. | 0 | 0 |
| 1575 | 0 | 0 | 876 2000 AMERICAN JOURNAL OF HUMAN GENETICS 67(4):134-134 Nippert I 40 years later: The health related quality of life of women affected by Thalidomide. | 0 | 0 |
| 1576 | 0 | 0 | 882 2000 ANNALS OF ONCOLOGY 11:54-54 Martinelli G; Mingrone W; Alietti A; Ferrucci F; Cocorocchio E; Peccatori F; Cinieri S; Corsini C; Zucca E; Bertolini F Clinical efficacy of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis | 0 | 0 |
| 1577 | 0 | 0 | 883 2000 ANNALS OF ONCOLOGY 11:60-60 Gasparini G; Gilberti S; Vitale S; Arena MG; Fanelli M; Ranieri G; Gattuso D; Biondi E; Morabito A Antitumoral activity of Thalidomide in patients affected by refractory breast cancer nad recurrent high grade gliomas. | 0 | 0 |
| 1578 | 0 | 0 | 884 2000 ANNALS OF ONCOLOGY 11:96-96 Galani E; Grigoraki V; Kiamouris C; Samantas E; Economou O; Papdimitriou C; Gika D; Anagnostopoulos N; Dimopoulos M Thalidomide and dexamethasone combination for refractory multiple myeloma. | 0 | 0 |
| 1579 | 0 | 0 | 885 2000 ANNALS OF ONCOLOGY 11:96-96 Mingrone W; Alietti A; Ferrucci F; Cocorocchio E; Peccatori F; Cinieri S; Corsini C; Zucca E; Bertolini F; Martinelli G Clinical efficacy and biologic activity of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis. | 0 | 0 |
| 1580 | 0 | 0 | 891 2000 ARTHRITIS AND RHEUMATISM 43(9):S117-S117 Lowe D; Kredich DW; Schanberg LE Thalidomide: An effective and safe agent for the treatment of pediatric mixed connective tissue disease. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1581 | 0 | 0 | 892 2000 ARTHRITIS AND RHEUMATISM 43(9):S396-S396 Huang F; Gu J; Braun J; Sieper J; Yu DT Identifying the targets of thalidomide and anti-TNF alpha antibody treatments in ankylosing spondylitis (AS). | 2 | 5 |
| 1582 | 0 | 0 | 897 2000 BLOOD 96(11):146A-146A Raza A; Lisak L; Little L; Ekbal M; du Rant M; Ali E; Nascimben F; Tareen M; Venugopal P Thalidomide as a single agent or in combination with topotecan, pentoxifylline and/or Enbrel in myelodysplastic syndromes (MDS). | 0 | 6 |
| 1583 | 0 | 0 | 898 2000 BLOOD 96(11):146A-146A Mundle S; Zorat F; Shetty V; Allampallam K; Alvi S; Lisak L; Little L; Dean L; Nascimben F; Ekbal M; duRandt M; Broderick E; Venugopal P; Raza A Biologic determinents of clinical response to thalidomide in myelodysplasia. | 0 | 3 |
| 1584 | 0 | 0 | 899 2000 BLOOD 96(11):167A-167A Yakoub-Agha I; Attal M; Dumontet C; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux I; Bay JO; Monconduit M; Harousseau JL; Duguet C; Facon T Thalidomide in patients with advanced myeloma: Survival prognostic factors. | 0 | 11 |
| 1585 | 0 | 0 | 900 2000 BLOOD 96(11):167A-167A Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. | 0 | 3 |
| 1586 | 0 | 0 | 901 2000 BLOOD 96(11):167A-167A Coleman M; Leonard JP; Nahum K; Michaeli J Non-myelosuppressive therapy with BLT-D (Biaxin (R), low dose thalidomide and dexamethasone) is highly active in Waldenstrom's macroglobulinemia and myeloma. | 0 | 10 |
| 1587 | 0 | 0 | 902 2000 BLOOD 96(11):167A-167A Weber DM; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide with dexamethasone for resistant multiple myeloma. | 0 | 26 |
| 1588 | 0 | 0 | 903 2000 BLOOD 96(11):168A-168A Kropff MH; Innig G; Mitterer M; Straka C; Ostermann H; Koch OM; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma. | 0 | 7 |
| 1589 | 0 | 0 | 904 2000 BLOOD 96(11):168A-168A Rajkumar SV; Hayman S; Fonseca R; Dispenzieri A; Lacy MQ; Geyer S; Wellik L; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM). | 0 | 24 |
| 1590 | 0 | 0 | 905 2000 BLOOD 96(11):168A-168A Weber DM; Rankin K; Gavino M; Delasalle K; Aguayo A; Albitar M; Alexanian R Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (MM). | 0 | 10 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1591 | 0 | 0 | 906 2000 BLOOD 96(11):168A-169A Raza SN; Veksler Y; Sabir T; Li ZJ; Anderson L; Jagannath S Durable response to thalidomide in relapsed/refractory multiple myeloma (MM). | 0 | 7 |
| 1592 | 0 | 0 | 907 2000 BLOOD 96(11):232B-232B Venugopal P; Sivaraman S; Gladstone B; Jajeh A; Huang XK; Brien TO; ODonnell K; Gregory S; Preisler H Thalidomide (T) influences antigen expression on tumor cells from chronic lymphocytic leukemia. | 0 | 0 |
| 1593 | 0 | 0 | 908 2000 BLOOD 96(11):260B-260B Dourado CMC; Seixas-Silva JA; Besa EC Response to thalidomide in 9 patients with myelodysplastic syndromes: A promising treatment for early or post-chemotherapy in late forms of MDS. | 0 | 1 |
| 1594 | 0 | 0 | 909 2000 BLOOD 96(11):261B-261B Lisak LA; Little L; Dean L; Ekbal M; duRandt M; Hussain M; Kaistha V; Raza A Delayed responses to thalidomide in patients with myelodysplastic syndromes. | 0 | 0 |
| 1595 | 0 | 0 | 910 2000 BLOOD 96(11):266B-266B Canepa L; Ballerini F; Varaldo R; Grasso R; Clavio M; Miglino M; Pierri I; Gobbi M Myelofibrosis: Report of five cases treated with thalidomide. | 0 | 1 |
| 1596 | 0 | 0 | 911 2000 BLOOD 96(11):285B-285B Badros A; Zangari M; Bodenner D; Siegel E; Spoon D; Toor A; Desikan R; Arnold E; Anaissie E; Zeldis J; Tricot G; Barlogie B Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide. | 0 | 3 |
| 1597 | 0 | 0 | 912 2000 BLOOD 96(11):286B-286B Dimopoulos MA; Viniou N; Zomas A; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotides P Treatment of Waldenstrom's macroglobulinemia with thalidomide. | 0 | 10 |
| 1598 | 0 | 0 | 913 2000 BLOOD 96(11):288B-288B Gibson RK; Alley L; Shuman HW Thalidomide (Thal) monotherapy is effective in previously treated recurrent multiple myeloma (MM). | 0 | 0 |
| 1599 | 0 | 0 | 914 2000 BLOOD 96(11):289B-289B Kakimoto T; Hattori Y; Okamoto S; Kamata T; Satoh N; Takayama N; Matsushita H; Yamada T; Du WL; Ikeda Y Thalidomide for the treatment of refractory multiple myeloma. Decreased plasma concentration of angiogenic growth factors and clinical response. | 0 | 0 |
| 1600 | 0 | 0 | 915 2000 BLOOD 96(11):290B-290B Moehler TM; Neben K; Hawighorst H; Egerer G; van Kaick G; Ho AD; Goldschmidt H Thalidomide plus CED chemotherapy as salvage therapy in poor prognosis multiple myeloma. | 0 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1601 | 0 | 0 | 916 2000 BLOOD 96(11):290B-290B Linder O; Tidefelt U Thalidomide combined with dexamethasone and pamidronate to patients with advanced myeloma, better than thalidomide alone? | 0 | 0 |
| 1602 | 0 | 0 | 917 2000 BLOOD 96(11):290B-290B Leleu X; Cornillon J; Magro L; Guillerm G; Dalle JH; Fenaux P; Jouet JP; Bauters F; Facon T; Yakoub-Agha I Is thalidomide 50 mg/d as a minimal first dose effective in advanced myeloma? | 0 | 2 |
| 1603 | 0 | 0 | 918 2000 BLOOD 96(11):292B-292B Palumbo A; Giaccone L; Bertola A; Bringhen S; Rus C; Triolo S; Pileri A; Boccadoro M Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma. | 0 | 6 |
| 1604 | 0 | 0 | 919 2000 BLOOD 96(11):293B-293B Prince HM; Biagi JJ; Mitchell P; Mileshkin L; Seymour JF; Januszewicz EH; Wolf MM; Westerman DA Interferon-alpha-2b (IF) can be combined with thalidomide (Thal) in patients with multiple myeloma (MM). | 0 | 3 |
| 1605 | 0 | 0 | 920 2000 BLOOD 96(11):294B-294B Rodriguez J; Oyama Y; Burt RK; Traynor AE Achievement of maximal disease response to thalidomide is limited by patient tolerance more often than disease resistance. | 0 | 4 |
| 1606 | 0 | 0 | 921 2000 BLOOD 96(11):294B-295B Srkalovic G; Karam MA; Trebisky BM; Hussein MA Treatment of refractory/relapsed multiple myeloma (MM) with combination of melphalan, thalidomide and decadron (MTD). | 0 | 1 |
| 1607 | 0 | 0 | 922 2000 BLOOD 96(11):296B-296B Tosi P; Ronconi S; Zamagni E; Cellini C; Tura S; Cavo M Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma. | 0 | 3 |
| 1608 | 0 | 0 | 923 2000 BLOOD 96(11):296B-296B Zangari M; Anaissie E; Desikan R; Badros A; Morris C; Munshi N; Gopal AV; Fink L; Spoon D; Tricot G; Barlogie B Thalidomide-induced hypercoagulability in multiple myeloma (MM). | 0 | 3 |
| 1609 | 0 | 0 | 924 2000 BLOOD 96(11):296B-296B Vescio RA; Berenson JR Thalidomide is an effective agent for patients with primary amyloidosis. | 0 | 1 |
| 1610 | 0 | 0 | 925 2000 BLOOD 96(11):304A-304A Hideshima T; Chauhan D; Shima Y; Noopur R; Davies FE; Tai YT; Treon SP; Lin BK; Schlossman RL; Richardson PG; Gupta D; Muller GW; Stirling DI; Anderson KC Thalidomide (Thal) and its analogs overcome drug resistance of human multiple myeloma (MM) cells to conventional therapy. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1611 | 0 | 0 | 926 2000 BLOOD 96(11):323A-323A Estey E; Albitar M; Cortes J; Giles F; Thomas D; Koller C; Beran M; Kantarjian H Addition of thalidomide(T) to chemotherapy did not increase remission rate in poor prognosis AML/MDS. | 0 | 13 |
| 1612 | 0 | 0 | 927 2000 BLOOD 96(11):356A-356A Alvi S; Henderson B; Shaher A; Dangerfield B; Broderick E; Jafri N; Tareen M; Du Randt M; Galili N; Borok RZ; Raza A Determination of clonality in stromal and parenchymal cells pre and post thalidomide treatment in myelodysplasia. | 0 | 0 |
| 1613 | 0 | 0 | 928 2000 BLOOD 96(11):359A-359A Alvi S; Shaher A; Henderson B; Dar S; Zorat F; Broderick E; Lisak L; Du Randt M; Reddy P; Mundle S; Galili N; Borok RZ; Raza A Improved growth of stromal cells in long term bone marrow cultures (LTBMC) of myelodysplastic syndrome (MDS) patients treated with thalidomide. | 0 | 1 |
| 1614 | 0 | 0 | 929 2000 BLOOD 96(11):364A-364A Yata K; Otsuki T; Yamada O; Yawata Y Expression of angiogenic factors including VEGFs, effects of anti-VEGF-A MoAb, hypoxia, and thalidomide on myeloma cells. | 0 | 0 |
| 1615 | 0 | 0 | 930 2000 BLOOD 96(11):364A-364A Rajkumar SV; Timm M; Mesa RA; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Gertz MA; Kyle RA; Griepp PR; Witzig TE Effect of thalidomide on myeloma cell apoptosis and VEGF secretion. | 0 | 5 |
| 1616 | 0 | 0 | 931 2000 BLOOD 96(11):366A-366A Petrucci MT; Ricciardi MR; Gregorj C; Palumbo G; Del Bianco P; Cartoni C; Mandelli F; Tafuri A Thalidomide effects on apoptosis in multiple myeloma: Ex-vivo and in vitro study. | 0 | 1 |
| 1617 | 0 | 0 | 932 2000 BLOOD 96(11):367B-367B Castro J; Talavera A; Tejeda C; Cortes L; Fradera J; Velez-Garcia E Preliminary experience of the use of thalidomide maintenance therapy after autologous transplant in patients with multiple myeloma (MM). | 0 | 0 |
| 1618 | 0 | 0 | 933 2000 BLOOD 96(11):368B-368B Dmoszynska A; Hus M; Legiec W; Walter-Croneck A; Wach M Delayed stem cell transplantation in patients with relapsed or refractory multiple myeloma using thalidomide as a preparative regimen. | 0 | 0 |
| 1619 | 0 | 0 | 934 2000 BLOOD 96(11):514A-514A Barlogie B; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 14 |
| 1620 | 0 | 0 | 935 2000 BLOOD 96(11):579A-+ Payvandi F; Wu L; Gupta D; Hideshima T; Haley M; Muller G; Chen R; Anderson KC; Stirling S Effects of a thalidomide analog on binding activity of transcription factors and cell cycle progression of multiple myeloma cell lines. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1621 | 0 | 0 | 936 2000 BLOOD 96(11):579A-+ Shaughnessy J; Zhan F; Tian E; Bumm K; Muller G; Stirling D; Tricot G; Barlogie B Global gene expression analysis shows loss of c-myc and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and IMiD. | 0 | 2 |
| 1622 | 0 | 0 | 937 2000 BLOOD 96(11):579A-+ Lentzsch S; Podar K; Davies FE; Hideshima T; Tai YT; Chauhan D; Lin BK; Treon SP; Gupta D; Mitsiades C; Mitsiades N; Hayashi T; Muller GW; Stirling DI; Anderson KC Immunomodulatory derivatives (IMiDs) of thalidomide (Thal) inhibit the proliferation of multiple myeloma (MM) cell lines and block VEGF-induced activation of the MAPK-pathway. | 0 | 2 |
| 1623 | 0 | 0 | 938 2000 BLOOD 96(11):746A-746A Piccaluga PP; Finelli C; Ricci P; Cavo M; Pileri SA; Isidori A; Malagola M; Grafone T; Tura S; Visani G Antiangiogenic therapy with thalidomide improves anemia, thrombocytopenia, hyperleucocytosis, splenomegaly in idiopathic myelofibrosis. | 0 | 4 |
| 1624 | 0 | 0 | 939 2000 BLOOD 96(11):746A-746A Barosi G; Grossi A; Comotti B; Marchetti M Thalidomide in patients with myelofibrosis with myeloid metaplasia. | 0 | 4 |
| 1625 | 0 | 0 | 940 2000 BLOOD 96(11):837A-837A Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin BK; Podar K; Chauhan D; Treon SP; Gupta D; Mitsiades C; Mitsiades N; Hayashi T; Richardson PG; Schlossman RL; Muller GW; Stirling DI; Anderson KC Thalidomide (Thal) and immunomodulatory derivatives (IMiDS) augment natural killer (NK) cell cytotoxicty in multiple myeloma (MM). | 0 | 2 |
| 1626 | 0 | 0 | 946 2000 BRITISH JOURNAL OF CANCER 83:31-31 Stebbing J; Benson C; Eisen T; Mak I; Pyle L; Smalley K; Gore ME A phase II study of high dose oral thalidomide in patients with metastatic renal cell carcinoma (RCC) or metastatic melanoma (MM) | 0 | 0 |
| 1627 | 0 | 0 | 951 2000 CA-A CANCER JOURNAL FOR CLINICIANS 50(1):3-3 [Anon] Once again, thalidomide in the news | 0 | 0 |
| 1628 | 0 | 0 | 955 2000 CHEMISTRY & INDUSTRY (16):522-522 [Anon] Health - Thalidomide patents granted in US | 0 | 0 |
| 1629 | 0 | 0 | 959 2000 CLINICAL CANCER RESEARCH 6:4522S-4523S Figg WD; Dahut W; Libutti SK; Carrasquillo J; Bacharach S; Kurdziel K; Huebsch F; Kruger EA; Pluda J; Reed E Thalidomide, an angiogenesis inhibitor, has activity in metastatic prostate cancer. | 0 | 0 |
| 1630 | 0 | 0 | 962 2000 CLINICAL INFECTIOUS DISEASES 31(1):312-312 Joyce MP; Sandoval FG; Shannon EJ Thalidomide's effect on immune parameters in untreated lepromatous leprosy and erythema nodosum leprosum | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1631 | 0 | 0 | 963 2000 CLINICAL PHARMACOLOGY & THERAPEUTICS 67(2):157-157 Noormohamed FH; Yoder L; Kook KA; Thomas SD Thalidomide pharmacokinetics in leprosy patients. | 0 | 0 |
| 1632 | 0 | 0 | 966 2000 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 125:S26-S27 Eichhorn A; Kirch W Thalidomide for Behcets syndrome | 0 | 0 |
| 1633 | 0 | 0 | 967 2000 DEVELOPMENTAL DYNAMICS 219(3):443-443 Fillmore BJ; Stephens TD Angiogenic integrin avb3 as a site of the teratogenic action of thalidomide | 0 | 0 |
| 1634 | 0 | 0 | 968 2000 DIABETES 49:A434-A434 Iqbal N; Boden G Thalidomide impairs insulin stimulated glucose uptake in patients with type 2 diabetes (T2DM) by inhibiting glycogen synthesis | 0 | 0 |
| 1635 | 0 | 0 | 970 2000 DRUG NEWS & PERSPECTIVES 13(3):146-146 [Anon] Celgene's IMiDS and thalidomide show activity as COX-2 inhibitors | 1 | 0 |
| 1636 | 0 | 0 | 974 2000 EUROPEAN HEART JOURNAL 21:367-367 Vescovo G; Ceconi C; Ferrari R; Ambrosio GB; Ravara B; Angelini A; Corti A; Rossini K; Sandri M; Leprotti C; Dalla Libera L Does thalidomide block apoptosis and prevent from the development of skeletal muscle myopathy in chronic heart failure? | 0 | 0 |
| 1637 | 0 | 0 | 976 2000 EXPERIMENTAL HEMATOLOGY 28(7):103-104 Raza A; Lisak L; Little L; Andrews C; Meyer P; Ekbal M; Venugopal P Improvement in cytopenias of patients with myelodysplastic syndromes (MDS) in response to thalidomide | 0 | 0 |
| 1638 | 0 | 0 | 977 2000 EXPERIMENTAL HEMATOLOGY 28(7):110-110 Janssen WE; Dalton WS Improved blood hematopoietic progenitor mobilization in myeloma patients following treatment with thalidomide | 0 | 0 |
| 1639 | 0 | 0 | 978 2000 FASEB JOURNAL 14(8):A1512-A1512 Cornely KA; Bennett NS Thalidomide makes a comeback: A case study exercise that integrates biochemistry and organic chemistry | 0 | 0 |
| 1640 | 0 | 0 | 979 2000 GASTROENTEROLOGY 118(4):A580-A580 Bauditz L; Wedel S; Suk A; Lochs H Cytokine profiles under treatment with Thalidomide steroid-resistant Crohn's disease. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1641 | 0 | 0 | 980 2000 GASTROENTEROLOGY 118(4):A582-A582 Kam LY; Vasiliauskas EA; Abreu MT; Hassard PV; Zeldis J; Targan SR Open labeled pilot study of thalidomide(thal) as a novel therapy for medically resistant ulcerative colitis (UC). | 1 | 6 |
| 1642 | 0 | 0 | 981 2000 GASTROENTEROLOGY 118(4):A586-A586 Prehn JL; Muller GW; Man HW; Stirling DJ; Targan SR Thalidomide analogs, but not thalidomide itself, are potent inhibitors of lamina propria mononuclear cell (LPMC) TNF-A and IFN-Gamma production in response to T cell stimuli. | 0 | 0 |
| 1643 | 0 | 0 | 983 2000 GESUNDHEITSWESEN 62(8-9):A87-A87 Edler B; Teige B; Nippert I Study on health-related quality of life among women with developmental retardation - Case of thalidomide victims | 0 | 0 |
| 1644 | 0 | 0 | 986 2000 HEPATOLOGY 32(4):410A-410A Enomoto N; Ikejima K; Hirose M; Ishikawa M; Konno A; Matsuyama S; Shimizu H; Kitamura T; Takei Y; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of TNF-A production by Kupffer cells. | 0 | 0 |
| 1645 | 0 | 0 | 993 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S180-S180 Velez G; King BA; Yuan P; Whitcup SM; Robison MR Thalidomide analogue (EM-138) sustained release implants to treat choroidal neovascularization associated with macular degeneration | 0 | 0 |
| 1646 | 0 | 0 | 994 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S604-S604 Spraul CW; Kaven C; Zavazava N; Lang GK; Lang GE Thalidomide and prednisolone inhibit growth factor-induced human RPE cell proliferation. | 0 | 0 |
| 1647 | 0 | 0 | 995 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S604-S604 Jakobezyk-Zmija M; Kaven C; Spraul CW; Lang GK; Lang GE Effect of thalidomide and prednisolone on the secretion of growth factors by human RPE cells in vitro | 0 | 0 |
| 1648 | 0 | 0 | 996 2000 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 41(4):S684-S684 Tham VMB; Tong JT; Giese MJ; Tran MK; Fardin B; Taban R; Rayner SA; Mondino BJ The effect of thalidomide on corneal graft rejection in rabbit eyes | 0 | 0 |
| 1649 | 0 | 0 | 1016 2000 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 35(2):172A-173A Bozkurt B; Chee A; Lee-Jackson D; Deswal A; Zeldis JB; Mann DL Results of an open label dose response study of thalidomide in patients with advanced heart failure and elevated levels of TNF | 0 | 2 |
| 1650 | 0 | 0 | 1019 2000 LEPROSY REVIEW 71:S120-S120 Ottenhoff THM; Kaplan G; Gillis TP Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions - Discussion | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1651 | 0 | 0 | 1025 2000 MOLECULAR BIOLOGY OF THE CELL 11:112A-112A Stevenson AN; Odoms S; Ezell T; Valentine S; Taylor L Does thalidomide reduce inflammation by altering cell adhesion molecule expression and cell-cell contacts on CEM cells? | 0 | 0 |
| 1652 | 0 | 0 | 1026 2000 MOLECULAR BIOLOGY OF THE CELL 11:452A-452A Ezell TN; Odoms S; Davis M; Taylor L Human T leukemic cells exhibit biochemical changes consistent with apoptosis after treatment with tumor necrosis factor alpha and thalidomide. | 0 | 0 |
| 1653 | 0 | 0 | 1029 2000 NEUROLOGY 54(7):A12-A13 Gupta A; Cohen BH; Ruggieri P; Packer RJ; Phillips P A phase I study of thalidomide for the treatment of plexiform neurofibroma in patients with neurofibromatosis 1 (NF1) | 0 | 0 |
| 1654 | 0 | 0 | 1034 2000 ONCOLOGY-NEW YORK 14(3):452-452 [Anon] Substantial activity of thalidomide in multiple myeloma, study shows | 0 | 0 |
| 1655 | 0 | 0 | 1035 2000 ONCOLOGY-NEW YORK 14(4):479-479 [Anon] Thalidomide active in advanced multiple myeloma | 0 | 0 |
| 1656 | 0 | 0 | 1036 2000 ONCOLOGY-NEW YORK 14(7):1081-1081 [Anon] Expanded data on thalidomide in advanced myeloma | 0 | 0 |
| 1657 | 0 | 0 | 1037 2000 ONCOLOGY-NEW YORK 14(12):9-10 Rajkumar SV Thalidomide in hematologic and oncologic disease - Proceedings of an Investigators' Meeting - May 20, 2000, New Orleans - Introduction | 2 | 2 |
| 1658 | 0 | 0 | 1046 2000 PEDIATRIC RESEARCH 47(4):264A-264A Hanekom W; Ganiso B; Appolis P; Hughes J; Allin R; Goddard E; Haslett P; Hussey G; Kaplan G Safety and immune effects of thalidomide in HIV-infected children | 0 | 0 |
| 1659 | 0 | 10 | 1051 2000 SEMINARS IN HEMATOLOGY 37(1):22-25 Alexanian R; Weber D Thalidomide for resistant and relapsing myeloma | 23 | 27 |
| 1660 | 0 | 68 | 1054 2000 SOCIAL STUDIES OF SCIENCE 30(1):41-71 Timmermans S; Leiter V The redemption of thalidomide: Standardizing the risk of birth defects | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1661 | 0 | 0 | 1062 2001 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U653-U653 Shi JD; Xiao ZL; Marks M; Kamat C; Pokala V Development of thalidomide analogs as anti-angiogenic agents. | 0 | 0 |
| 1662 | 0 | 0 | 1063 2001 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U659-U659 Xiao ZL; Schaefer K; Li PK Solid phase synthesis of thalidomide and its analogs. | 0 | 0 |
| 1663 | 0 | 0 | 1064 2001 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 222:U685-U685 Luzzio FA; Figg WD; Mayorov AV; Kruger EA Thalidomide metabolites and analogs, part 3: Synthesis and antiangiogenic activity of the teratogenic and TNF-alpha-modulatory thalidomide analog EM-12. | 0 | 0 |
| 1664 | 0 | 0 | 1079 2001 ARTHRITIS AND RHEUMATISM 44(9):S125-S125 Barthel HR Successful treatment of Weber Christian disease (WCD) with thalidomide in a patient failing multiple other medical therapies | 0 | 0 |
| 1665 | 0 | 0 | 1080 2001 ARTHRITIS AND RHEUMATISM 44(9):S272-S272 Lehman TJ; Striegel KH; Onel KB Thalidomide therapy for corticosteroid dependent systemic onset juvenile rheumatoid arthritis | 0 | 1 |
| 1666 | 0 | 0 | 1081 2001 ARTHRITIS AND RHEUMATISM 44(9):S275-S275 Huang F; Gu JR; Zhao W; Zhu J; Zhang JL; Yu DTY Therapeutic effect and molecular targets of thalidomide in refractory ankylosing spondylitis (AS). | 0 | 2 |
| 1667 | 0 | 0 | 1082 2001 ARTHRITIS AND RHEUMATISM 44(9):S280-S280 Cuadrado MJ; Smith E; Gordon P; Karim Y; Khamashta MA; Hughes GRV Thalidomide: Efficacy and safety in 30 patients with lupus and skin involvement. | 0 | 0 |
| 1668 | 0 | 0 | 1097 2001 BLOOD 98(11):52B-52B Anders O; Plath F; Emmrich J; Freund M Complete remission of therapy-resistant angiodysplasia of the stomach in myelodysplastic syndrome following thalidomide. | 0 | 0 |
| 1669 | 0 | 0 | 1098 2001 BLOOD 98(11):52B-52B Arkel YS; Ku DHW; Le P Effect of thalidomide on tissue factor activity in monocytic and endothelial cell lines, and relationship to tumor necrosis factor-alpha (TNF). | 0 | 0 |
| 1670 | 0 | 0 | 1099 2001 BLOOD 98(11):161A-162A Zangari M; Siegel E; Anaissie E; Saghafifar F; Morris C; Fink L; Barlogie B; Tricot G Risk factors for deep vein thrombosis (DVT) in a large group of myeloma patients (pts) treated with thalidomide (Thal): The Arkansas experience. | 0 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1671 | 0 | 0 | 1100 2001 BLOOD 98(11):162A-162A Palumbo A; Giaccone L; Bringhen S; Cavallo F; Falco P; Rus C; Bertola A; Pileri A; Boccadoro M Low dose thalidomide and dexamethasone are as effective as oral melphalan and prednisone in refractory and relapsed myeloma patients. | 0 | 4 |
| 1672 | 0 | 0 | 1101 2001 BLOOD 98(11):162A-162A Kakimoto T; Hattori Y; Okamoto S; Sato N; Yamaguchi M; Morita K; Yamada T; Takayama N; Shimada N; Tanigawara Y; Ikeda Y Clinical significance of serial monitoring of plasma concentration of thalidomide and angiogenic growth factors in patients with refractory myeloma. | 0 | 1 |
| 1673 | 0 | 0 | 1102 2001 BLOOD 98(11):162A-162A Wechalekar AD; Sutton D; Voralia M; Stewart AK; Chen CI Intermediate dose thalidomide (200mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. | 0 | 5 |
| 1674 | 0 | 0 | 1103 2001 BLOOD 98(11):162A-163A Rajkumar SV; Dispenzieri A; Lacy M; Geyer S; Iturria N; Fonseca R; Hayman SR; Lust JA; Kyle R; Greipp PR; Gertz MA; Witzig TE Response rate and durablity of response with thalidomide therapy for relapsed multiple myeloma (MM). | 0 | 4 |
| 1675 | 0 | 0 | 1104 2001 BLOOD 98(11):163A-163A Durie BGM; Stepan DE Low dose thalidomide alone and in combination: Long term follow-up. | 0 | 6 |
| 1676 | 0 | 0 | 1105 2001 BLOOD 98(11):163A-163A Tosi P; Zamagni E; Cellini C; Cangini D; Tura S; Baccarani M; Cavo M Rapid response and early relapse after thalidomide plus dexamethasone salvage therapy in patients with advanced relapsed and refractor multiple myeloma. | 0 | 3 |
| 1677 | 0 | 0 | 1106 2001 BLOOD 98(11):163A-163A Alexanian R; Weber DM; Giralt S; Delasalle KB Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. | 0 | 2 |
| 1678 | 0 | 0 | 1107 2001 BLOOD 98(11):163A-163A Neben K; Moehler TM; Benner A; Kraemer A; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide (Thal) on overall survival (OS) in relapsed and refractory multiple myeloma (MM). | 0 | 0 |
| 1679 | 0 | 0 | 1108 2001 BLOOD 98(11):163A-163A Grosbois B; Bellissant E; Moreau P; Attal M; Zerbib R Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients. | 0 | 5 |
| 1680 | 0 | 0 | 1109 2001 BLOOD 98(11):164A-164A Dimopoulos M; Panayiotidis P; Grigoraki V; Poziopoulos C; Xilouri I; Kiamouris C; Tassidou A; Gika D; Stefanoudaki K; Anagnostopoulos N; Anagnostou D Oral hyperfractionated cyclophosphamide and intermittent thalidomide-dexamethasone for previously treated patients with multiple myeloma. | 0 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1681 | 0 | 0 | 1110 2001 BLOOD 98(11):164A-164A Seldin DC; Choufani E; Skinner M; Wright DG; Dember L; Weisman J; Fennessey S; Finn K; Sanchorawala V A phase I/II trial of thalidomide for patients with AL amyloidosis. | 0 | 1 |
| 1682 | 0 | 0 | 1111 2001 BLOOD 98(11):182B-182B Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Yalcin A Terminal differentiation and apoptosis of myeloid leukemia induced by thalidomide and rhGM-CSF combination. | 0 | 0 |
| 1683 | 0 | 0 | 1112 2001 BLOOD 98(11):215B-215B Manson SD; Venugopal P; Gregory SA; Raza A; Sivaraman S; Preisler H Treatment of relapsed/refractory acute myeloid leukemia (AML) with thalidomide as a single agent: Clinical and biologic responses. | 0 | 0 |
| 1684 | 0 | 0 | 1113 2001 BLOOD 98(11):222B-222B Sivaraman S; Venugopal P; Hu WY; Gladstone B; Galili N; Nair A; Manjali J; Mogongwa A; Zhao HP; Manson S; Preisler H Effect of thalidomide as a single agent on serum cytokine levels in patients with relapsed acute myeloid leukemia. | 0 | 0 |
| 1685 | 0 | 0 | 1114 2001 BLOOD 98(11):246B-246B Pro B; Younes A; Albitar M; Hagemeister FB; Rodriguez MA; McLaughlin P; Clemons M; Samaniego F; Cabanillas F Phase II study of thalidomide in patients with recurrent Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL). | 0 | 0 |
| 1686 | 0 | 0 | 1115 2001 BLOOD 98(11):271B-271B Fabbri A; Biscardi M; Innocenti F; Balestri F; Gavazzi S; Bellesi G; Grossi A Thalidomide in combination with amifostine in the treatment of MDS: Evaluation of clinical and laboratory findings. | 0 | 0 |
| 1687 | 0 | 0 | 1116 2001 BLOOD 98(11):273B-273B Raza A; Lisak L; Dutt D; Dean L; Fantroy L; Syed E; Gezer S; Hsu WT; Goldberg C; Loew J; Venugopal P Combination of thalidomide with pentoxifylline, ciprofloxacin, and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS). | 0 | 0 |
| 1688 | 0 | 0 | 1117 2001 BLOOD 98(11):273B-274B Raza A; Dutt D; Lisak L; Dean L; Fantroy L; Gezer S; Syed E; Goldberg C; Loew J; Hsu WT; Venugopal P Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic syndromes (MDS). | 0 | 0 |
| 1689 | 0 | 0 | 1118 2001 BLOOD 98(11):296B-297B Dmoszynska A; Rolinski J; Bojarska-Junak A; Manko J; Jawniak D; Walter-Croneck A; Soroka-Wojtaszko M; Hus M; Domanski D Influence of thalidomide on bcl-2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow lymphocyte subsets of multiple myeloma patients. | 0 | 0 |
| 1690 | 0 | 0 | 1119 2001 BLOOD 98(11):307B-307B Ahmad I; Alam AR; Hahn T; Becker J; Chanan-Khan AA; Czuczman M; Bernstein S; Bernstein Z; McCarthy P Thalidomide plus VAD (vincristine, doxorabicin and dexamethasone) salvage therapy for VAD-refractory multiple myeloma, prior to autologous peripheral blood stem cell transplant (PBSCT). | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1691 | 0 | 0 | 1120 2001 BLOOD 98(11):307B-307B Bibas M; Andriani A; Ferrari A; Montanaro M; Niscola G; Recine U; Chierichini A Thalidomide treatment for relapsed/refractory multiple myeloma: A retrospective multicenter study. | 0 | 0 |
| 1692 | 0 | 0 | 1121 2001 BLOOD 98(11):307B-307B Alegre A; Macias GR; Granda A; Golbano N; Martinez E; Alaez C; Blazquez C; Gongora E; Cannata J; Sanchez-Godoy P; Martinez-Chamorro C; Arranz R; de Soria VGG; Figuera A; Arranz E; Fernandez-Ranada JM Thalidomide as rescue treatment of relapses after haematopoietic transplantation in multiple myeloma. | 0 | 0 |
| 1693 | 0 | 0 | 1122 2001 BLOOD 98(11):308B-308B Grosbois B; Bellissant E; Muret E; Voillat L; Zerbib R Measurement of seric thalidomide (Thal) level in patients treated for advanced multiple myeloma (MM). | 0 | 2 |
| 1694 | 0 | 0 | 1123 2001 BLOOD 98(11):309B-309B Kasper B; Moehler TM; Neben K; Ho AD; Goldschmidt H Response to a combination therapy of thalidomide and Pegintron (R) in patients with progressive multiple myeloma (MM). | 0 | 1 |
| 1695 | 0 | 0 | 1124 2001 BLOOD 98(11):310B-310B Mohty M; Stoppa AM; Blaise D; Isnardon D; Gastaut JA; Olive D; Gaugler B Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide: Implications for multiple myeloma therapy. | 0 | 0 |
| 1696 | 0 | 0 | 1125 2001 BLOOD 98(11):311B-311B Offidani M; Mele A; Marconi M; Corvatta L; Candela M; Pieroni S; Malerba L; Rupoli S; Olivieri A; Leoni P Thalidomide plus melphalan in relapsed-refractory multiple myeloma. | 0 | 1 |
| 1697 | 0 | 0 | 1126 2001 BLOOD 98(11):311B-311B Avalos JS; Barazzutti L; Korin J; Kusminsky G; Ferro H; Tavella O; Foncuberta M; Tartas N Thalidomide and cranial nerves neuropathies. | 0 | 0 |
| 1698 | 0 | 0 | 1127 2001 BLOOD 98(11):313B-313B Womeldorph JL; Myhand RC; Monahan BP Reversible acute renal failure following initiation of thalidomide therapy in a patient with relapsed multiple myeloma. | 0 | 0 |
| 1699 | 0 | 0 | 1128 2001 BLOOD 98(11):351A-352A Alvi S; Shaher A; Shaikh M; Anthwal S; Siddiqi F; Akhtar A; Ashraf H; Meagher R; Mundle S; Shetty V; Goldberg C; Galili N; Borok RZ; Raza A MDS patients with hematological response to thalidomide show enhanced in vitro growth potential. | 0 | 0 |
| 1700 | 0 | 0 | 1129 2001 BLOOD 98(11):352A-352A Alvi S; Shaikh M; Anthwal S; Shaher A; Tamoseviciene D; Novick A; Reddy P; Allampallam K; Hsu WT; Galili N; Borok RZ; Raza A Cytogenetic and clonal profile of myelodysplastic syndromes (MDS) patients treated with thalidomide. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1701 | 0 | 0 | 1130 2001 BLOOD 98(11):353A-354A Baker AF; Bellamy WT; Glinsmann-Gibson BJ; Heaton R; Buresh A; Grogan TM; List AF Biological response to thalidomide in remitting patients with myelodysplastic syndrome (MDS): Evidence for induction of neoplastic vascular endothelial growth factor (VEGF) resistance. | 0 | 0 |
| 1702 | 0 | 0 | 1131 2001 BLOOD 98(11):365B-365B Game M; Coso D; Sturgeon J; Crump M; Keating A Thalidomide and low dose vinblastine as palliative therapy for patients relapsing after autotransplant for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). | 0 | 1 |
| 1703 | 0 | 0 | 1132 2001 BLOOD 98(11):373A-374A Uziel O; Shapira A; Radnay J; Lahav M; Lishner M Thalidomide downregulates transcript levels of GC-rich promoter genes in multiple myeloma. | 0 | 0 |
| 1704 | 0 | 0 | 1133 2001 BLOOD 98(11):395B-395B Moehler TM; Neben K; Kasper B; Kordelas L; Egerer G; Goerner M; Ho AD; Goldschmidt H Thalidomide plus CED chemotherapy as remission induction regimen for poor prognosis multiple myeloma patients before autologous or allogeneic stem cell transplantation. | 0 | 0 |
| 1705 | 0 | 0 | 1134 2001 BLOOD 98(11):622A-622A Musto P; Falcone A; Bodenizza C; Sanpaolo G; Matera R; Bisceglia M; Carella AM Thalidomide (THAL) significantly improves anemia in selected transfusion-dependent patients with myelodysplastic syndromes (MDS): Relationship to serum and marrow levels of angiogenetic growth factors (AGF). | 0 | 3 |
| 1706 | 0 | 0 | 1135 2001 BLOOD 98(11):627A-627A Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt R; Geyer GM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia (MMM). | 0 | 1 |
| 1707 | 0 | 0 | 1136 2001 BLOOD 98(11):685A-685A Somlo G; Yamamoto N; Sarah C; O'Donnell M; Snyder D; Sahebi F; Kogut N; Spielberger R; Molina A; Parker P; Popplewell L; Fung H; Rodriguez R; Stein A; Krishnan A; Chow W; Lopez F; Forman S Tandem cycle high-dose melphalan and intravenous busulfan/cytoxan with peripheral blood progenitor cell rescue (PBPC) followed by interferon alpha-2 (IF) with, or without thalidomide (Thal) for multiple myeloma. High complete response rate and moderate toxicities. | 0 | 1 |
| 1708 | 0 | 0 | 1137 2001 BLOOD 98(11):775A-775A Richardson PG; Schlossman RL; Hideshima T; Davies F; LeBlanc R; Catley L; Doss D; Kelly KA; McKenney M; Mechlowicz J; Freeman A; Deocampo R; Rich R; Ryoo J; Chauhan D; Munshi N; Weller E; Thomas S; Zeldis J; Anderson KC A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM). | 0 | 10 |
| 1709 | 0 | 0 | 1138 2001 BLOOD 98(11):775A-775A Mitsiades N; Mitsiades CS; Poulaki V; Akiyama M; Tai YT; Lin BK; Hayashi T; Catley L; Hideshima T; Chauhan D; Treon SP; Anderson KC Apoptotic signaling induced by immunomodulatory thalidomide analogs (IMiDs) in human multiple myeloma cells: Therapeutic implications. | 0 | 1 |
| 1710 | 0 | 0 | 1139 2001 BLOOD 98(11):849A-849A Rajkumar SV; Hayman SR; Gertz MA; Dispenzieri A; Lacy M; Greipp PR; Geyer S; Itturia N; Fonseca R; Lust JA; Kyle R; Witzig TE Combination therapy with thalidomide plus dexamethasone (THAL/DEX) for newly diagnosed myeloma (MM). | 0 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1711 | 0 | 0 | 1140 2001 BLOOD 98(11):849A-849A Neben K; Mytilineos J; Moehler TM; Preiss A; Kraemer A; Ho AD; Goldschmidt H Genetic polymorphism in the tumor necrosis factor-alpha locus influences the outcome to thalidomide therapy in relapsed and refractory multiple myeloma (MM). | 0 | 1 |
| 1712 | 0 | 0 | 1141 2001 BLOOD 98(11):863A-863A Bennett CL; Schumok GT; Kwaan HC; Raisch DW High incidence of thalidomide-associated deep vein thrombosis and pulmonary emboli when chemotherapy is also administered. | 0 | 3 |
| 1713 | 0 | 0 | 1143 2001 BONE MARROW TRANSPLANTATION 27:S251-S252 Hus M; Dmoszynska A; Legiec W; Jawniak D; Soroka-Wojtaszko M; Manko J Thalidomide as a preparative regimen and late stem cell transplantation in patients with relapsed or refractory multiple myeloma | 0 | 0 |
| 1714 | 0 | 0 | 1167 2001 CIRCULATION 104(17):123-123 Yang E; Matcuk G; Zhang Y; Talbi S; Chen M; Ho M; Liao C; Tsao PS; Quertermous T; Deng D; Sampas N; Ach R; Love W Anti-angiogenic effects of thalidomide characterized by transciptional profiling of endothelial cell-specific gene expression | 0 | 0 |
| 1715 | 0 | 0 | 1168 2001 CIRCULATION 104(17):566-566 Kishan CV; Saucedo JF; Fahdi I; Gaddam V; Razek H; Bissett JK; Anaissie E; Barlogie B; Mehta JL High dose thalidomide is associated with symptomatic bradycardia | 0 | 0 |
| 1716 | 0 | 0 | 1174 2001 CLINICAL CANCER RESEARCH 7(11):3666S-3667S Hsu C; Chen C; Chen L; Wu C; Hsieh F; Cheng A Use of thalidomide in the treatment of advanced hepatocellular carcinoma (HCC): With emphasis on using power Doppler sonography to evaluate the vascularity of the tumor and its correlation with tumor response. | 0 | 0 |
| 1717 | 0 | 0 | 1175 2001 CLINICAL LYMPHOMA 2(1):16-17 [Anon] Thalidomide shows promise in previously untreated and refractory multiple myeloma | 0 | 0 |
| 1718 | 0 | 0 | 1180 2001 DIABETES 50:A473-A473 Bosco A; Lerario AC; Santos RF; Ferreira A; Ursich MJ; Silva ME; Rocha DM; Wajchenberg BL Study of Thalidomide and Rosiglitazone effects on the prevention of diabetic retinopathy of Streptozotocin diabetic rats | 0 | 0 |
| 1719 | 0 | 0 | 1190 2001 FASEB JOURNAL 15(4):A556-A556 Jajeh A; Boulos B; Youakim J; Ali M; Woynarowsky A In vitro reduction of accelerated apoptosis of neutrophils in blood drawn from an HIV positive subject with Thalidomide. | 0 | 0 |
| 1720 | 0 | 0 | 1191 2001 FREE RADICAL BIOLOGY AND MEDICINE 31:S54-S54 Hansen JM; Gong SG; Harris C Thalidomide (TD) depletes glutathione and alters gene expression in the developing limb. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1721 | 0 | 0 | 1192 2001 GASTROENTEROLOGY 120(5):A278-A278 Stein DJ; Rafiee P; Taras A; Lamirand TH; Fisher PJ; Ogawa H; Telford GL; Otterson MF; Johnson CP; Binion DG Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). | 0 | 0 |
| 1722 | 0 | 0 | 1193 2001 GASTROENTEROLOGY 120(5):A611-A612 Khan ZH; Cole AT; MacDonald I; Pye D; Austin A; Freeman JG The role of thalidomide in reversing cachexia in patients with inoperable oesophageal cancers | 0 | 0 |
| 1723 | 0 | 0 | 1196 2001 GUT 48:A48-A48 Khan ZH; Cole AT; Macdonald I; Pye D; Simpson L; Austin A; Freeman JG The role of thalidomide in reversing cachexia in patients with inoperable oesophageal cancer | 0 | 0 |
| 1724 | 0 | 0 | 1197 2001 GUT 48:A67-A68 Austin AS; Mahida YR; Ryder SD; Freeman JG Thalidomide but not pentoxifylline lowers portal pressure in human alcoholic cirrhosis | 0 | 0 |
| 1725 | 0 | 0 | 1198 2001 GUT 48:A89-A90 Trebble T; Johns T; Duncan HD; Goggin PM An open trial of thalidomide in refractory Crohn's colitis | 0 | 0 |
| 1726 | 0 | 2 | 1199 2001 HAEMATOLOGICA 86(4):348-348 [Anon] Thalidomide in the treatment of multiple myeloma | 0 | 0 |
| 1727 | 0 | 0 | 1203 2001 HAEMATOLOGICA 86(4):448-448 Zappasodi P; Lorenzi A; Corso A Thalidomide in refractory myeloma patients: early changes in bone marrow cellularity | 1 | 1 |
| 1728 | 0 | 0 | 1209 2001 HEPATOLOGY 34(4):279A-279A Muriel P; Fernandez-Martinez E; Perez-Alvarez VM; Morales-Rios MS A thalidomide analog with hepatoprotective and antifibrotic properties in biliary obstruction-induced cirrhosis in the rat. | 0 | 0 |
| 1729 | 0 | 0 | 1210 2001 HEPATOLOGY 34(4):516A-516A Muriel P; Ponce S; Garcia JC Thalidomide partially prevents CCl4-induced liver cirrhosis. | 0 | 0 |
| 1730 | 0 | 0 | 1211 2001 HEPATOLOGY 34(4):517A-517A Muriel P; Garcia JC; Ponce S; Perez-Alvarez VM; Fernandez-Martinez E; Morales-Rios MS Synthesis and pharmacological evaluation of a thalidomide analog, the 3-phthalimido-3-(3,4-dimethoxyphenyl)propanoic acid in liver cirrhosis induced by bile duct ligation in the rat. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1731 | 0 | 0 | 1215 2001 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 42(4):S233-S233 Maguire MG; Fine SL; Maguire AM; D'Amato RJ; Singerman LJ Results of the age-related macular degeneration and thalidomide study (AMDATS). | 0 | 5 |
| 1732 | 0 | 0 | 1217 2001 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 286(8):909-909 Mitka M Thalidomide battles myeloma | 1 | 0 |
| 1733 | 0 | 0 | 1227 2001 JOURNAL OF HEPATOLOGY 34:18-18 Austin AS; Mahida YR; Ryder SD; Freeman JG Thalidomide but not pentoxifylline lowers portal pressure in human alcoholic cirrhosis | 0 | 0 |
| 1734 | 0 | 5 | 1237 2001 LANCET ONCOLOGY 2(10):634-635 Hwu WJ; Raizer J; Panageas KS; Lis E Treatment of metastatic melanoma in the brain with temozolomide and thalidomide | 3 | 7 |
| 1735 | 0 | 0 | 1238 2001 LEUKEMIA 15(3):491-491 Barlogie D; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 0 |
| 1736 | 0 | 1 | 1241 2001 LIBRARY JOURNAL 126(7):126-126 Kupferberg N Dark remedy: The impact of thalidomide and its revival as a vital medicine. | 0 | 0 |
| 1737 | 0 | 0 | 1243 2001 MOLECULAR BIOLOGY OF THE CELL 12:23A-23A Ezell TN Apoptotic cell death induced by low doses of the tumor necrosis alpha inhibitor, thalidomide in human T leukemic cells | 0 | 0 |
| 1738 | 0 | 1 | 1245 2001 NATURE 410(6827):411-412 Dormandy T Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
| 1739 | 0 | 0 | 1247 2001 NEUROLOGY 56(8):A208-A209 Khella SL; Souayah N; AMDATS Study Grp Thalidomide polyneuropathy: A prospective double-masked placebo-controlled study in an elderly population with age-related macular degeneration | 0 | 0 |
| 1740 | 0 | 1 | 1251 2001 NEW YORK REVIEW OF BOOKS 48(8):12-15 Horton R Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1741 | 0 | 0 | 1252 2001 ONCOLOGY-NEW YORK 15(3):301-301 [Anon] Thalidomide analogs active against multiple myeloma | 0 | 0 |
| 1742 | 0 | 0 | 1253 2001 ONCOLOGY-NEW YORK 15(4):493-+ [Anon] Thalidomide studied in a variety of cancers and metabolic disorders | 0 | 0 |
| 1743 | 0 | 0 | 1264 2001 RADIOLOGY 221:387-387 Faria SC; Charnsangavej C; Sawaf Y; Hess KR; Tamm EP; Lee T CT quantification of antiangiogenic effects of thalidomide | 0 | 0 |
| 1744 | 0 | 0 | 1279 2002 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 224:U21-U21 Hu ZG; Zink J; Zili X; Shi JD; Li PK Anti-angiogenic and anti-proliferative thalidomide analogs. | 0 | 0 |
| 1745 | 0 | 16 | 1285 2002 AMERICAN BIOLOGY TEACHER 64(7):495-500 Seidman LA; Warren NN Frances Kelsey & thalidomide in the US: A case study relating to pharmaceutical regulations | 0 | 0 |
| 1746 | 0 | 0 | 1287 2002 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 59(18):1700-+ Young D Thalidomide prescribers cannot assign survey responsibility to pharmacists | 0 | 0 |
| 1747 | 0 | 21 | 1292 2002 ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY 88(4):421-424 Medeiros M; Araujo MI; Guimaraes NS; Freitas LAR; Silva TMC; Carvalho EM Therapeutic response to thalidomide in Melkersson-Rosenthal syndrome: a case report | 1 | 2 |
| 1748 | 0 | 1 | 1300 2002 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 46(7):2313-2313 Tsenova L; Mangaliso B; Muller G; Chen Y; Freedman VH; Stirling D; Kaplan G Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis (vol 46, pg 1889, 2002) | 0 | 0 |
| 1749 | 0 | 0 | 1303 2002 ARTHRITIS AND RHEUMATISM 46(9):S290-S290 Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GRV Thalidomide in lupus: Efficacy and toxicity are not dose-dependent. | 0 | 0 |
| 1750 | 0 | 0 | 1304 2002 ARTHRITIS AND RHEUMATISM 46(9):S480-S481 Schwartz KH; Agle LMA; Lehman TJA Thalidomide therapy of systemic onset JIA: Continued success. | 0 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1751 | 0 | 0 | 1326 2002 BLOOD 100(11):15B-15B Carneiro JDA; Garanito M; Halsman M; Matsumoto L; Odone V; del Giglio A Thalidomide as salvage therapy for acquired severe aplastice anemia (SAA) in children - Case report | 0 | 0 |
| 1752 | 0 | 0 | 1327 2002 BLOOD 100(11):71A-71A Mesa RA; Li CY; Steensma DP; Pardanani A; Elliott MA; Kaufmann SH; Gray L; Schroeder GS; Tefferi A A combination of low dose thalidomide with prednisone in myelofibrosis with myeloid metaplasia. | 0 | 0 |
| 1753 | 0 | 0 | 1328 2002 BLOOD 100(11):75B-75B Kaushal V; Kaushal GP; Anaissie EJ; Kurylo P; Kohli M; Fink LM; Mehta P Thalidomide-induced coagulopathy: Evidence for an indirect effect on endothelium. | 0 | 0 |
| 1754 | 0 | 0 | 1329 2002 BLOOD 100(11):96A-96A List AF; Kurtin SE; Glinsmann-Gibson BJ; Bellamy WT; Buresh AJ; Waddleton D; Knight R High erythropoietic remitting activity of the immunomodulatory thalidomide analog, CC5013, in patients with myelodysplastic syndrome (MDS). | 0 | 3 |
| 1755 | 0 | 0 | 1330 2002 BLOOD 100(11):96A-96A Moreno-Aspitia A; Geyer S; Li CY; Tefferi A; Witzig T; Niedrinhaus RD; Vukov AM; Morton R; Fitch T; Addo FE; Dakhil SR; Tschetter L; Colon-Otero G N998B: Multicenter phase II trial of thalidomide (Thal) in adult patients with myelodysplastic syndromes (MDS). | 0 | 1 |
| 1756 | 0 | 0 | 1331 2002 BLOOD 100(11):105A-105A Zangari M; Barlogie B; Prather J; Eddlemon P; Anaissie E; Lee CK; Tricot G; Thertulien R; van Rhee F Marked activity also in del 13 multiple myeloma (MM) of PS 341 (PS) and subsequent thalidomide (THAL) in a setting of resistance to post-autotransplant salvage therapies. | 0 | 5 |
| 1757 | 0 | 0 | 1332 2002 BLOOD 100(11):139A-139A List AF; Tate W; Glinsmann-Gibson BJ; Baker A The immunomodulatory thalidomide analog, CC5013, inhibits trophic response to VEGF in AML cells by abolishing cytokine-induced PI3-kinase/Akt activation. | 0 | 1 |
| 1758 | 0 | 0 | 1333 2002 BLOOD 100(11):162A-162A Drach J; Kaufmann H; Puespoek A; Bankier A; Urbauer E; Chott A; Raderer M Marked anti-tumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma. | 0 | 1 |
| 1759 | 0 | 0 | 1334 2002 BLOOD 100(11):170A-170A Neben K; Mytilineos J; Kraemer A; Moehler TM; Preiss A; Ho AD; Opelz G; Goldschmidt H Thalidomide is able to improve the outcome in patients carrying the high producer haplotype of the interleukin-10 gene promoter in multiple myeloma. | 0 | 0 |
| 1760 | 0 | 0 | 1335 2002 BLOOD 100(11):178A-178A Brinker B; Waller EK; Langston AA; Redei I; Smith KJ; Bucur SZ; Winton E; Lyles R; Heffner LT; Lonial S Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1761 | 0 | 0 | 1336 2002 BLOOD 100(11):209A-209A Weber D; Ginsberg C; Walker P; Obolendt M; Rankin K; Gavino M; Delasalle K; Alexanian R Correlation of thrombotic/embolic events (T/E) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide-dexamethasone (TD). | 0 | 3 |
| 1762 | 0 | 0 | 1337 2002 BLOOD 100(11):210A-210A Barlogie B; Tricot G; Anaissie E; Fassas A; Lee CK; Thertulien R; van Rhee F; Zangari M Long-term follow-up (median of 4 yr) of 169 patients receiving thalidomide (THAL) for advanced and refractory multiple myeloma (MM): Superior survival in the absence of cytogenetic abnormalities (CA) and low beta-2 microglobulin (B2M). | 0 | 0 |
| 1763 | 0 | 0 | 1338 2002 BLOOD 100(11):211A-211A Palumbo A; Bertola A; Cavallo F; Falco P; Bringhen S; Giaccone L; Musto P; Pregno P; Boccadoro M Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma. | 0 | 3 |
| 1764 | 0 | 0 | 1339 2002 BLOOD 100(11):211A-211A Myers B; Jones SG; McMillan AK; Dolan G Zoledronic acid, hypocalcaemia and renal dysfunction in thalidomide-treated myeloma patients. | 0 | 0 |
| 1765 | 0 | 0 | 1340 2002 BLOOD 100(11):265B-265B Manson SD; Gregory SA; Rogers K; Raza A; Loew J; Hsu WT; Sivaraman S; Venugopal P Thalidomide as a single agent leads to meaningful responses in older patients with poor prognosis acute myeloid leukemia (PP-AML) | 0 | 0 |
| 1766 | 0 | 0 | 1341 2002 BLOOD 100(11):314B-314B Hayashi T; Anderson KC; Steven SP Rituximab induced antibody dependent cell mediated cytotoxicity (ADCC) is enhanced by thalidomide and its analogue revimid. | 0 | 1 |
| 1767 | 0 | 0 | 1342 2002 BLOOD 100(11):336B-336B Musto P; Falcone A; Sanpaolo G; Bodenizza C; Bisceglia M; Matera R; Minervini MM; Carella AM Does thalidomide act with different mechanisms of action in myelodysplastic syndromes? | 0 | 0 |
| 1768 | 0 | 0 | 1343 2002 BLOOD 100(11):337B-337B Shetty V; Alvi S; Zorat F; Patkar S; Zahid S; Khan T; Mundle S; Galili N; Reddy P; Alvi M; Lisak L; Gezer S Effect of the anti-angiogenic agent thalidomide on the biological characteristics of patients with myelodysplastic syndromes. | 0 | 0 |
| 1769 | 0 | 0 | 1344 2002 BLOOD 100(11):340B-340B Raza A; Lisak LA; Tahir S; Billmeier JM; Willmann HS; Alvi MI; Bellak DJ; Gezer S; Venugopal P Combination of thalidomide and etanercept (Tumor necrosis factor receptor OR TNFR) effective in improving the cytopenias of some patients with myelodysplastic syndromes (MDS). | 0 | 2 |
| 1770 | 0 | 0 | 1345 2002 BLOOD 100(11):341B-341B Islam A; Bielat K; Smith G Does thalidomide have an effect other than anti-angiogenesis. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1771 | 0 | 0 | 1346 2002 BLOOD 100(11):346B-346B Grossi A; Gavazzi S; Biscardi M; Balestri F; Bonsi L; Bagnara G; Pierdomenico L; Mazzucconi F Thalidomide therapy effects on angiogenic growth factors (VEGF, TGF-beta) and KDR expression in myeloid metaplasia with myelofibrosis. | 0 | 1 |
| 1772 | 0 | 0 | 1347 2002 BLOOD 100(11):367B-367B Luo SK; Li J; Hong WD; Zhou ZH Immunoreactivity of thalidomide in patients with multiple myeloma. | 0 | 0 |
| 1773 | 0 | 0 | 1348 2002 BLOOD 100(11):371B-371B Payvandi F; Wu L; Zhang LH; Muller G; Chen R; Stengel J; Harriri R; Stirling D Thalidomide and IMiDs inhibit microvessel formation from human arterial rings in the absence of human liver microsomes. | 0 | 0 |
| 1774 | 0 | 0 | 1349 2002 BLOOD 100(11):375A-375A Alvi S; Borok RZ; Shaher A; Anthwal S; Shaikh M; Alvi I; Tahir S; John P; Shetty V; Galili N; Raza A Thalidomide significantly modifies bone marrow microenvironment in myelodysplastic syndrome (MDS) patients. | 0 | 0 |
| 1775 | 0 | 0 | 1350 2002 BLOOD 100(11):377B-377B Lincz LF; Enno A Thalidomide induced alterations in multiple myeloma cell surface receptor expression do not affect adhesion to bone marrow stroma or correlate with VEGF secretion in vitro. | 0 | 0 |
| 1776 | 0 | 0 | 1351 2002 BLOOD 100(11):380B-380B Waage A; Romstad L; Brenne AT; Gimsing P; Juliusson G; Turesson I; Borset M; Sundan A Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma. | 0 | 1 |
| 1777 | 0 | 0 | 1352 2002 BLOOD 100(11):384B-384B Devabhaktuni YD; Laber DA Secondary plasma cell leukemia associated with thalidomide in a patient with multiple myeloma. | 0 | 0 |
| 1778 | 0 | 0 | 1353 2002 BLOOD 100(11):384B-384B Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Anagnostopoulos N; Gika D; Margaritis D; Economopoulos T Clarithromycin, thalidomide and dexamethasone for the treatment of Waldenstrom's macroglobulinemia. | 0 | 0 |
| 1779 | 0 | 0 | 1354 2002 BLOOD 100(11):384B-384B Fawaz A; Magro L; Leleu X; Depil S; Guillerm G; Corm S; Bauters F; Facon T; Yakoub-Agha I Impact of thalidomide on survival of patients with multiple myeloma. | 0 | 2 |
| 1780 | 0 | 0 | 1355 2002 BLOOD 100(11):385B-385B Caravita T; Arciprete F; Siniscalchi A; Santinelli S; Iani C; Amadori S Thalidomide induced neuropathy in patients treated for multiple myeloma. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1781 | 0 | 0 | 1356 2002 BLOOD 100(11):387B-387B Helgason HH; Smit WM; de Groot MR; Schenkeveld CEI; Neef C; Schaafsma MR Long term survival and complete remission of chemotherapy refractory multiple myeloma with thalidomide. | 0 | 0 |
| 1782 | 0 | 0 | 1357 2002 BLOOD 100(11):387B-387B Dmoszynska A; Manko J; Jawniak D; Ciepluch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Soroka-Wojtaszko M; Urbanska-Rys H; Konopka L; Hus M Toxicity of thalidomide in multiple myeloma patients (long-term observations). | 0 | 0 |
| 1783 | 0 | 0 | 1358 2002 BLOOD 100(11):387B-387B Meng HT; Jin J; Mai WY Thalidomide plus M2 chemotherapy in the treatment of refractory multiple myeloma. | 0 | 0 |
| 1784 | 0 | 0 | 1359 2002 BLOOD 100(11):388B-388B Musto P; Falcone A; Sanpaolo G; La Sala A; Mantuano S; Cascavilla N; Melillo L; Dell'Olio M; Nobile M; Bodenizza C; Carella AM A combined therapy with thalidomide, dexamethasone and zoledronate is highly effective and well tolerated in pre-treated patients with multiple myeloma. | 0 | 1 |
| 1785 | 0 | 0 | 1360 2002 BLOOD 100(11):389B-389B Keyzner A; Kumar A; Besa EC The role of thalidomide and pamidronate in maintenance of plateau phase after second and third induction therapy in relapsed multiple myeloma patients. | 0 | 0 |
| 1786 | 0 | 0 | 1361 2002 BLOOD 100(11):389B-389B Huang JW; Wang YH; Du HP; Zhang J Thalidomide combined with conventional melphalan and predisone regimen for treatment of mulitiple myeloma | 0 | 0 |
| 1787 | 0 | 0 | 1362 2002 BLOOD 100(11):390B-390B Breitkreutz I; Cremer FW; Benner A; Raab MS; Moehler T; Egerer G; Christensen O; Herrmann D; Ho AD; Goldschmidt H Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF in multiple myeloma: No influence of previous thalidomide (Thai) administration. | 0 | 0 |
| 1788 | 0 | 0 | 1363 2002 BLOOD 100(11):390B-390B Sato N; Kakimoto T; Hattori Y; Okamoto S; Morita K; Tanigawara Y; Ikeda Y Thalidomide induced severe neutropenia during the treatment of multiple myeloma via direct suppression of bone marrow hematopoiesis. | 0 | 0 |
| 1789 | 0 | 0 | 1364 2002 BLOOD 100(11):390B-390B Sidra GM; Russell N; Byrne J; Myers B; Mitchell D Combination therapy with thalidomide, cyclophosphamide and dexamethasone (C-ThaD) for VAD-refractory and relapsed myeloma. | 0 | 0 |
| 1790 | 0 | 0 | 1365 2002 BLOOD 100(11):390B-390B Alegre A; Gil-Fernandez JJ; Font P; Alonso A; Sureda A; Martinez-Chamorro C; Escudero A; Sanchez-Godoy P; Burgaleta C; Casado LF; Granda A; Aguado B; Osorio S; Nistal S; Mascunano R; Prieto E; Fernandez-Ranada JM Thalidomide as rescue of relapses after haematopoietic transplantation in multiple myeloma and as maintenance treatment: Results of a Spanish multicentre study including 63 patients. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1791 | 0 | 0 | 1366 2002 BLOOD 100(11):392B-392B Kazmi MA; Cuadrado MJ; Karim MY; Jones RJ; Khamashta MA; Schey SA Comparison of thalidomide toxicity profiles in treatment of Lupus and myeloma: Efficacy and toxicity are not dose dependent. | 0 | 0 |
| 1792 | 0 | 0 | 1367 2002 BLOOD 100(11):393B-393B Moehler TM; Schlenzka J; Kasper B; Neben K; Egerer G; Ho AD; Goldschmidt H Low incidence of deep venous thrombosis in poor prognosis multiple myeloma patients treated with thalidomide and CED chemotherapy. | 0 | 0 |
| 1793 | 0 | 0 | 1368 2002 BLOOD 100(11):393A-393A Bahlis NJ; Sawney R; Gerson S PKC delta inhibition induces cell death in thalidomide and dexamethasone resistant multiple myeloma cell lines. | 0 | 0 |
| 1794 | 0 | 0 | 1369 2002 BLOOD 100(11):394A-395A Minnema MM; Fijnheer R; De Groot PG; Lokhorst HM Factor VIII procoagulant activity as risk factor for deep venous thrombosis in patients with Multiple Myeloma during treatment with thalidomide. | 0 | 0 |
| 1795 | 0 | 0 | 1370 2002 BLOOD 100(11):397A-397A Palladini G; Perfetti V; Obici L; Merlini G Thalidomide toxicity in patients with AL (primary) amyloidosis. | 0 | 4 |
| 1796 | 0 | 0 | 1371 2002 BLOOD 100(11):398A-398A Zangari M; Barlogie B; Anaissie FJ; Saghafifar F; Fassas A; Lee CK; Thertulien R; van Rhee F; Zeldis J; Fink L; Tricot G Abrogation of thrombogenic effect of the doxorubicin (DOX)- thalidomide (THAL) combination as part of total therapy II (TTII) for newley diagnosed multiple myeloma (MM) by effective anti-coagulation with low molecular weight heparin (LMWH). | 0 | 2 |
| 1797 | 0 | 0 | 1372 2002 BLOOD 100(11):398A-398A Dispenzieri A; Lacy MQ; Rajkumar SV; Geyer SM; Fonseca R; Witzig TE; Lust JA; Greipp PR; Kyle RA; Gertz MA High doses of thalidomide are not well tolerated in patients with primary systemic amyloidosis. | 0 | 2 |
| 1798 | 0 | 0 | 1373 2002 BLOOD 100(11):401A-402A Prince M; Mileshkin L; Biagi JJ; Smith JG; Mitchell P; Underhill C; Grigg A; Bell R; McKendrick J; Briggs P; Seymour JF; Simmons PJ; Zeldis JB A multicentre phase-II trial of thalidomide in relapsed/refractory multiple myeloma (MM) reveals a dominant adverse prognostic impact of advanced age. | 0 | 0 |
| 1799 | 0 | 0 | 1374 2002 BLOOD 100(11):402A-402A Oakervee HE; McBride NC; Hemmaway CJ; Brownell A; Cervi P; Crawley C; Gale R; Grant I; Hamblin M; Lewis D; Rahemtulla A; Barnett MJ; Cavenagh JD Thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) is effective treatment for multiple myeloma and does not prejudice successful stem cell harvesting. | 0 | 2 |
| 1800 | 0 | 0 | 1375 2002 BLOOD 100(11):402A-403A Kropff MH; Lang N; Bisping G; Domine N; Schneider P; Suedhoff T; Innig G; Straka C; Ostermann H; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in advanced multiple myeloma: Final results of a phase II trial. | 0 | 1 |